Genetically Targeted Therapeutic Looks Promising for Alcohol Use Disorder
AD04 is a genetically targeted, serotonin-3 receptor antagonist that is believed to reduce alcohol intake by interfering with the dopamine reward system.
AD04 is a genetically targeted, serotonin-3 receptor antagonist that is believed to reduce alcohol intake by interfering with the dopamine reward system.
Individual consumers are not restricted from having or using JUUL products; however, the Agency will ensure compliance by retailers.
Pharmacodynamic studies have shown that nalmefene has a longer duration of action than naloxone.
Researchers used data from the State Unintentional Drug Overdose Reporting System in order to assess trends in gabapentin-involved overdose deaths.
The Strategy focuses on 2 main drivers of the opioid epidemic: drug trafficking and untreated addiction.
Naloxone Auto-Injector is specifically designed to be a medical countermeasure for military personnel or chemical incident responders against the potential threat of exposure to synthetic opioids on the battlefield.
The FDA defines acute pain as pain, lasting up to 30 days, typically in response to some form of tissue injury, such as trauma or surgery.
The investigational intranasal formulation of nalmefene demonstrated a more rapid onset and longer duration of action compared with naloxone.
Zimhi is intended for immediate administration as emergency therapy in settings where opioids may be present.
Par’s generic version of Chantix is currently the only available one in the US.